IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImmunityBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$8.42−0.76 (-8.28%)
Close on Oct 19, 2026
- Market cap
- $8.84B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
99.3%
Operating margin
-226.0%+36283.1 pts over 5 years
Net margin
-310.2%+36359.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +668.3% | +678.6% | +184.8% | +85.4% | |
| Gross profit | +663.2% | +676.9% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -37.2% | -50941.7% | 71.0% | |
| Return on assets | -35.3% | -121.7% | -79.4% | |
| Current ratio | 16.34 | 1.64 | 5.10 | |
| Interest coverage | -1886.4× | -24.3× | -4.2× | |
| Inventory turnover | – | – | 0.2× | |
| Capex to revenue | 14909.1% | 275.9% | 3.4% | |
| Diluted shares | 82M | 377M | 920M |
Where the cash went
Fiscal 2021 to 2025, five years combined
ImmunityBio generated $1.67B from operations and spent $153.04M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.67B
Used
$153.04M
Capital expenditure$153.04M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-310.2%
×Asset turnover0.26×
×Equity multiplier-0.89×
=Return on equity, FY202571.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -310.2% | 0.26× | -0.89× | 71.0% |
| FY2024 | -2804.8% | 0.03× | -0.82× | 76.9% |
| FY2023 | -93761.4% | 0.00× | -0.84× | 112.8% |
| FY2022 | -173569.6% | 0.00× | -1.21× | 120.8% |
| FY2021 | -37129.6% | 0.00× | -1.91× | 191.6% |
| FY2020 | -36669.6% | 0.00× | 418.49× | -50941.7% |
| FY2019 | -7165.2% | 0.01× | 1.22× | -118.3% |
| FY2018 | -204736.2% | 0.00× | 1.19× | -52.7% |
| FY2017 | -214273.3% | 0.00× | 1.11× | -37.6% |
| FY2016 | -274565.9% | 0.00× | 1.05× | -37.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$351.40M
- Cash generatingOperating cash flow above zero-$304.94M
- Return on assets improvedROA up on the prior year-82.0% → -91.8%
- Earnings backed by cashOperating cash flow above net income-$304.94M vs -$351.40M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.36 → 5.10
- No dilutionShare count did not rise700M → 920M
- Gross margin improvedGross margin up on the prior year100.00% → 99.34%
- More efficientAsset turnover rose0.03 → 0.30